DCM
CGEM icon

DAFNA Capital Management’s Cullinan Oncology CGEM Stock Holding History

DAFNA Capital Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-127,284
Closed -$1.3M – 75
2023
Q4 		$1.3M Hold
127,284
– – 0.31% 56
2023
Q3 		$1.15M Buy
+127,284
New +$1.33M 0.36% 53

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

DAFNA Capital Management's CGEM Position: Q1 2024 in Review

DAFNA Capital Management sold out of Cullinan Oncology (CGEM) in Q1 2024, closing a stake of 127,284 shares — an estimated $1.3M sold.

DAFNA Capital Management first reported a position in CGEM in Q3 2023 and held it in 2 quarters. The position peaked at $1.3M in Q4 2023. 113 funds tracked by Wall St. Rank hold CGEM as of Q1 2024.

  • DAFNA Capital Management reported no remaining Cullinan Oncology position as of Q1 2024 after selling out during the quarter.
  • DAFNA Capital Management sold 127,284 Cullinan Oncology shares in Q1 2024, an estimated $1.3M.
  • DAFNA Capital Management first reported a position in Cullinan Oncology in Q3 2023 and held it in 2 quarters.
  • DAFNA Capital Management's Cullinan Oncology position peaked at $1.3M in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2024.

Based on DAFNA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.